Meclizine
Antivert, Meclizine (meclizine) is a small molecule pharmaceutical. Meclizine was first approved as Antivert on 1982-01-01. It is used to treat motion sickness, vertigo, and vomiting in the USA. It is known to target nuclear receptor subfamily 1 group I member 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Antivert, Meclizine (discontinued: Meclizine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Meclizine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ANTIVERT | Casper Pharma | N-010721 RX | 1982-01-01 | 4 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| antivert | New Drug Application | 2022-10-18 |
| bonine | C200263 | 2021-07-06 |
| bonine max | OTC monograph final | 2022-10-05 |
| cvs motion sickness fast melting | C200263 | 2023-11-03 |
| diphen | ANDA | 2022-07-11 |
| dramamine | C200263 | 2024-10-25 |
| dramamine - n | C200263 | 2024-10-25 |
| dramamine less drowsy | C200263 | 2024-01-05 |
| jet-avert motion sickness aid | C200263 | 2023-12-15 |
| less drowsy formula motion sickness relief | C200263 | 2024-08-24 |
Show 25 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| vomiting | HP_0002013 | D014839 | R11.1 |
| vertigo | — | D014717 | H81.39 |
| motion sickness | — | D009041 | T75.3 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Motion sickness | D009041 | — | T75.3 | — | 1 | — | 2 | — | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | 1 | 1 | — | — | 1 | 2 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | 1 | — | — | — | 1 |
| Space motion sickness | D018489 | EFO_1001188 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | — | 1 | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 1 | 1 |
| Benign paroxysmal positional vertigo | D065635 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Meclizine |
| INN | meclozine |
| Description | Meclizine is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 569-65-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1623 |
| ChEBI ID | 6709 |
| PubChem CID | 4034 |
| DrugBank | DB00737 |
| UNII ID | 3L5TQ84570 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NR1I3
NR1I3
Organism
Homo sapiens
Gene name
NR1I3
Gene synonyms
CAR
NCBI Gene ID
Protein name
nuclear receptor subfamily 1 group I member 3
Protein synonyms
CAR, Constitutive activator of retinoid response, constitutive active receptor, Constitutive active response, Constitutive androstane receptor, orphan nuclear hormone receptor, Orphan nuclear receptor MB67
Uniprot ID
Mouse ortholog
Nr1i3 (12355)
nuclear receptor subfamily 1 group I member 3 (O35627)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Meclizine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,273 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,689 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use